We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

GVI Clinical Development Solutions and Guangzhou IRD Medicine Company Create Global CRO

Read time: Less than a minute

GVI Clinical Development Solutions Inc. (CDS), headquartered in Winnipeg, Canada and Guangzhou, China based Guangzhou IRD Medicine Company, have announce the signing of a Memorandum of Understanding to create a joint venture company called IRD-CDS, based in China.

IRD-CDS is committed to providing excellence in clinical development services and expertise in the conduct of clinical trials.

"We are very pleased to have formalized our relationship with Guangzhou IRD Medicine Company through the creation of IRD-CDS," commented Jan-Ake Westin, President of CDS. "Their in-depth knowledge of the life science industry in China combined with our team's expertise in conducting global clinical trials makes for a strong partnership that is ready to meet the needs of clinical stage companies."

IRD-CDS' flexibility and active participation during the critical stages of the clinical development process make it an ideal clinical partner for life science companies who want to take advantage of the expanding clinical trial environment in China.

The CDS group has tremendous global experience in clinical research trials and strong relationships within the industry. Current clients include world class research hospitals, multinational and emerging life science companies.

IRD-CDS is a full service contract research organization supporting biotechnology, pharmaceutical, diagnostic, medical device, and nutraceutical companies looking to conduct Phase II & III clinical trials in China.